Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates morphine-like analgesia without respiratory depression or addiction liability in mice, suggesting minimal mu opioid receptor activation can achieve safe pain relief.
Mitragynine and 7-hydroxymitragynine (7OH) are the major alkaloids mediating the biological actions of the psychoactive plant kratom.To investigate the structure-activity relationships of mitragynine/7OH templates, we diversified the aromatic ring of the indole at the C9, C10, and C12 positions and investigated their G-protein and arrestin signaling mediated by mu opioid receptors (MOR).Three synthesized lead C9 analogs replacing the 9-OCH 3 group with phenyl (4), methyl (5), or 3′-furanyl [6 (SC13)] substituents demonstrated partial agonism with a lower efficacy than DAMGO or morphine in heterologous G-protein assays and synaptic physiology.In assays limiting MOR reserve, the G-protein efficacy of all three was comparable to buprenorphine.6 (SC13) showed MOR-dependent analgesia with potency similar to morphine without respiratory depression, hyperlocomotion, constipation, or place conditioning in mice.These results suggest the possibility of activating MOR minimally (G-protein E max ≈ 10%) in cell lines while yet attaining maximal antinociception in vivo with reduced opioid liabilities.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: